Dr. Sagar Lonial on Lenalidomide Versus Observation in Smoldering Myeloma

Sagar Lonial, MD, discusses an ongoing phase III trial investigating if any interventions would change the natural history of smoldering myeloma.

Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses an ongoing phase III trial investigating if any interventions would change the natural history of smoldering myeloma. Lonial says only intermediate and high-risk patients are enrolled in the study, and these patients are randomized to either lenalidomide or observation.